America Is About to Go over a Peptide Cliff
4 hours ago
- BPC-157, a peptide rumored to heal various conditions, has surged in popularity due to influencers and RFK Jr., with many users sourcing it from unregulated online vendors.
- An FDA advisory committee voted 8-6 to recommend allowing compounding pharmacies to produce BPC-157, despite weak safety data and lack of FDA approval.
- The recommendation may lead to FDA approval given RFK Jr.'s enthusiasm, potentially opening a lucrative market for telehealth companies like Hims and Noom.
- Proponents argue that regulated compounding pharmacies are safer than the unregulated gray market, while critics warn it could falsely imply FDA endorsement.
- Other peptides (TB-500, KPV, MOTS-c) were also recommended; Emideltide was rejected, with more votes pending.